Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Nova Pneuma Inc. Clear all
Completed Phase 2 Interventional Results available

Staccato Prochlorperazine in Migraine (Out Patient)

NCT00422812
View directory record Official record
Conditions
Migraine Headache, Aura
Interventions
Inhaled Placebo, Inhaled PCZ 5 mg, Inhaled PCZ 7.5 mg, Inhaled PCZ 10 mg
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 70 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
25
States / cities
Scottsdale, Arizona • San Francisco, California • Santa Monica, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Staccato Zaleplon Single Dose Pharmacokinetics

NCT00620620
View directory record Official record
Conditions
Healthy
Interventions
Inhaled placebo, Inhaled Zaleplon 0.5 mg, Inhaled Zaleplon 1 mg, Inhaled Zaleplon 2 mg, Inhaled Zaleplon 4 mg
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Staccato Alprazolam Abuse Liability

NCT00603980
View directory record Official record
Conditions
Abuse Liability of Staccato Alprazolam
Interventions
Inhaled placebo + oral placebo, Inhaled alprazolam 0.5 mg, Inhaled alprazolam 1 mg, Inhaled alprazolam 2 mg, Oral alprazolam 1 mg, Oral alprazolam 2 mg, Oral alprazolam 4 m, Oral alprazolam 2 mg qualifying session, Oral placebo qualifying session
Drug
Lead sponsor
Nova Pneuma Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Staccato Prochlorperazine Single Dose PK Study

NCT00610727
View directory record Official record
Conditions
Migraine
Interventions
Prochlorperazine 0.5 mg IV over 5 sec, Inhaled prochlorperazine 0.625 mg, Inhaled prochlorperazine 1.25 mg, Inhaled prochlorperazine 2.5 mg, Inhaled prochlorperazine 5 mg, Inhaled prochlorperazine 10 mg, Inhaled placebo, Prochlorperazine 10 mg IV over 5 sec
Drug
Lead sponsor
Nova Pneuma Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 2 Interventional Results available

Staccato Alprazolam in Panic Attack

NCT00477451
View directory record Official record
Conditions
Treatment of Induced Panic Attack
Interventions
Inhaled placebo, Inhaled alprazolam 1 mg, Inhaled alprazolam 2 mg, IV doxapram
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 2 Interventional Results available

Staccato Loxapine in Migraine (Out Patient)

NCT00825500
View directory record Official record
Conditions
Migraine Headache
Interventions
Inhaled Placebo, Inhaled Loxapine 1.25 mg, Inhaled Loxapine 2.5 mg
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
3
States / cities
Springfield, Missouri • Mount Vernon, New York • East Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 23, 2017 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 2 Interventional Results available

Staccato Alprazolam and Photoparoxysmal Response

NCT02351115
View directory record Official record
Conditions
Epilepsy
Interventions
A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 m, D= Inhaled Alprazolam 2 mg, E=Placebo
Drug
Lead sponsor
Nova Pneuma Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Boise, Idaho • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Staccato Loxapine Pulmonary Safety in Patients With COPD

NCT00889837
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Inhaled Loxapine, Inhaled Placebo
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
40 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 1 Interventional

Staccato Loxapine Multidose PK

NCT00555412
View directory record Official record
Conditions
Volunteers on Chronic, Stable Antipsychotic Regimens
Interventions
A - 10 mg loxapine q 4 h x 3 (30 mg total), B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total), C - 5 mg loxapine q 4 h x 3 (15 mg total), D - inhaled placebo q 4 h x 3
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Staccato Prochlorperazine in Migraine (in Clinic)

NCT00610428
View directory record Official record
Conditions
Migraine Headache, With or Without Aura
Interventions
Staccato Placebo, Staccato Prochlorperazine 5 mg, Staccato Prochlorperazine 10 mg
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Mount Vernon, New York
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Staccato Prochlorperazine Thorough QT/QTc

NCT00543062
View directory record Official record
Conditions
Cardiotoxicity
Interventions
Inhaled placebo, Oral placebo, Inhaled prochlorperazine 5 mg, Inhaled prochlorperazine 10 mg, Oral moxifloxacin
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 10, 2019 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Staccato® Granisetron Single Dose PK

NCT04200092
View directory record Official record
Conditions
Healthy
Interventions
0.5mg AZ-010; placebo, 1mg AZ-010, 3mg AZ-010, AZ-010 1mg, IV Granisetron 1mg, Placebo
Combination Product · Drug · Other
Lead sponsor
Nova Pneuma Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Staccato Fentanyl Single and Multidose PK

NCT00402350
View directory record Official record
Conditions
Breakthrough Pain
Interventions
Inhaled Placebo, Inhaled Fentanyl 25 mcg, Intravenous Fentanyl 25 mcg, Inhaled Fentanyl 25 mcg x 2, Inhaled Fentanyl 25 mcg x 4, Inhaled Fentanyl 25 mcg x 6, Inhaled Fentanyl 25 mcg x 12
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Sep 1, 2026, 10:27 PM EDT
Terminated Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes

NCT05979415
View directory record Official record
Conditions
Parkinson Disease
Interventions
Apomorphine Cartridge
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
30 Years to 85 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
13
States / cities
Scottsdale, Arizona • Tucson, Arizona • Fountain Valley, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Staccato Loxapine in Migraine (in Clinic)

NCT00489476
View directory record Official record
Conditions
Migraine
Interventions
Staccato Loxapine, Staccato Placebo
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Wellesley Hills, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Staccato Loxapine PK in Smokers and Nonsmokers

NCT00873769
View directory record Official record
Conditions
Smoking, Cigarette
Interventions
Inhaled Loxapine 10 mg
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
20 Years to 50 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Sep 1, 2026, 10:27 PM EDT
Suspended No phase listed Observational

Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder

NCT03513549
View directory record Official record
Conditions
Agitation,Psychomotor
Interventions
Loxapine 10 MG
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 3 Interventional Results available

Staccato Loxapine in Agitated Patients With Bipolar Disorder

NCT00721955
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Inhaled Placebo, Inhaled loxapine 5 mg, Inhaled loxapine 10 mg
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
6
States / cities
Escondido, California • Garden Grove, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Staccato Loxapine Pulmonary Safety in Patients With Asthma

NCT00890175
View directory record Official record
Conditions
Asthma
Interventions
Inhaled loxapine @ 0 & 10 h, Inhaled placebo @ 2 & 10 hours
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome

NCT04645953
View directory record Official record
Conditions
Cyclic Vomiting Syndrome
Interventions
3mg AZ-010, 1mg AZ010, Staccato Placebo
Combination Product
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 60 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
18
States / cities
Lancaster, California • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Staccato Loxapine Single Dose PK

NCT00444028
View directory record Official record
Conditions
Schizophrenia
Interventions
inhaled Loxapine 0.625 mg, inhaled Loxapine 1.25 mg, inhaled Loxapine 2.5 mg, inhaled Loxapine 5 mg, inhaled Loxapine 10 mg, inhaled Placebo (0 mg)
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

ADASUVE-Lorazepam Drug-Drug Interaction

NCT01877642
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Lorazepam 1 mg IM, Inhaled loxapine 10 mg, Inhaled Placebo, Placebo IM
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Staccato Loxapine Pulmonary Safety in Healthy Volunteers

NCT00789360
View directory record Official record
Conditions
Healthy
Interventions
Inhaled Placebo, Inhaled Loxapine
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
North Dartmouth, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 10, 2019 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 2 Interventional Results available

Staccato Loxapine in Agitation (Proof of Concept)

NCT00369577
View directory record Official record
Conditions
Schizophrenia
Interventions
Inhaled Placebo, Inhaled Loxapine 5 mg, Inhaled Loxapine 10 mg
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Upland, California
Source: ClinicalTrials.gov public record
Updated Jan 1, 2018 · Synced Sep 1, 2026, 10:27 PM EDT